GIRAUD, Julie; CHALOPIN, Domitille; RAMEL, Eloïse; BOYER, Thomas; ZOUINE, Atika; DERIEPPE, Marie-Alix; LARMONIER, Nicolas; ADOTEVI, Olivier; LE BAIL, Brigitte; BLANC, Jean-Frédéric; LAURENT, Christophe; CHICHE, Laurence; DERIVE, Marc; NIKOLSKI, Macha; SALEH, Maya

doi:10.1016/j.celrep.2024.113773

Institut de biochimie et génétique cellulaires [IBGC]

CHALOPIN, Domitille
Institut de biochimie et génétique cellulaires [IBGC]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

RAMEL, Eloïse
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

Langue

Article de revue

Ce document a été publié dans

Cell Reports. 2024-02, vol. 43, n° 2

Résumé en anglais

Hepatocellular carcinoma (HCC) is an inflammation-associated cancer arising from viral or non-viral etiologies including steatotic liver diseases (SLDs). Expansion of immunosuppressive myeloid cells is a hallmark of inflammation and cancer, but their heterogeneity in HCC is not fully resolved and might underlie immunotherapy resistance. Here, we present a high-resolution atlas of innate immune cells from patients with HCC that unravels an SLD-associated contexture characterized by influx of inflammatory and immunosuppressive myeloid cells, including a discrete population of THBS1+ regulatory myeloid (Mreg) cells expressing monocyte- and neutrophil-affiliated genes. THBS1+ Mreg cells expand in SLD-associated HCC, populate fibrotic lesions, and are associated with poor prognosis. THBS1+ Mreg cells are CD163+ but distinguished from macrophages by high expression of triggering receptor expressed on myeloid cells 1 (TREM1), which contributes to their immunosuppressive activity and promotes HCC tumor growth in vivo. Our data support myeloid subset-targeted immunotherapies to treat HCC.< Réduire

Mots clés en anglais

Liver cancer

Steatohepatitis

Immunotherapy

Innate immunity

Myeloid cells

TREM1

Inflammation

Hepatocellular carcinoma

Metabolism

URI

https://oskar-bordeaux.fr/handle/20.500.12278/204782

DOI

http://dx.doi.org/10.1016/j.celrep.2024.113773

Unités de recherche

ImmunoConcEpT - UMR 5164

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche